Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Nivolumab |
| Synonyms | |
| Therapy Description |
Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma (UC) , esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) for melanoma, renal cell carcinoma (RCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy for PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy for metastatic or recurrent NSCLC without EGFR or ALK alterations, with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, with Cabometyx (cabozantinib) for advanced RCC, with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, GEJ cancer, and esophageal adenocarcinoma, and with cisplatin and gemcitabine as first-line treatment for unresectable or metastatic UC (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Nivolumab | Opdivo | MDX-1106|BMS-936558 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma (UC) , esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) for melanoma, renal cell carcinoma (RCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy for PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy for metastatic or recurrent NSCLC without EGFR or ALK alterations, with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, with Cabometyx (cabozantinib) for advanced RCC, with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, GEJ cancer, and esophageal adenocarcinoma, and with cisplatin and gemcitabine as first-line treatment for unresectable or metastatic UC (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN positive | melanoma | sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Opdivo (nivolumab) (PMID: 26645196). | 26645196 |
| PBRM1 S681R | clear cell renal cell carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in partial response in a patient with renal clear cell carcinoma harboring PBRM1 S681R (PMID: 29301960). | 29301960 |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Nivolumab | Guideline | Actionable | Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). | detail... |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). | 27225694 |
| PBRM1 K621* | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 K621* (PMID: 29301960). | 29301960 |
| PBRM1 A249fs | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 A249fs (PMID: 29301960). | 29301960 |
| PBRM1 G2fs | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 G2fs (PMID: 29301960). | 29301960 |
| PBRM1 Y608fs | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 Y608fs (PMID: 29301960). | 29301960 |
| BRAF V600K | melanoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828). | 30630828 |
| MSH6 negative | endometrial carcinoma | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). | detail... |
| MSH6 negative | endometrial carcinoma | sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial, Opdivo (nivolumab) treatment resulted in an objective response rate of 58.8% (20/34, 7 complete and 13 partial responses) and a progression-free survival rate at 24 mo of 64.7% in patients with MSI-high or deficient mismatch repair (dMMR defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) ovarian or endometrial carcinoma, including responses in 2 patients with uterine clear cell carcinoma and 1 patient with ovarian clear cell carcinoma (PMID: 38653864; NCT03241745). | 38653864 |
| PBRM1 E291* | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 E291* (PMID: 29301960). | 29301960 |
| MSH6 negative | small intestine adenocarcinoma | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | Advanced Solid Tumor | predicted - sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), a median progression-free survival (PFS) of 6.3 mo, a 6-month PFS rate of 51.3%, and a median overall survival of 17.3 months (PMID: 31765263; NCT02465060). | 31765263 |
| BRAF V600E | melanoma | decreased response | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828). | 30630828 |
| NRAS mutant | melanoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, NRAS mutations were associated with higher 6-month objective response rate (53.3% vs. 19.6% without NRAS mutations; p=0.019) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma, however, progression-free survival and overall survival were similar between patients with and without NRAS mutations (PMID: 29973670). | 29973670 |
| PBRM1 K154fs | clear cell renal cell carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in partial response in a patient with renal clear cell carcinoma harboring PBRM1 K154fs (PMID: 29301960). | 29301960 |
| PBRM1 mutant | clear cell renal cell carcinoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, PBRM1 truncating mutations were associated with response to Opdivo (nivolumab) with 39% (15/38) of responding patients harboring PBRM1 mutations vs 22% (16/74) of non-responders, as well as clinical benefit (p=0.0497), increased progression-free survival (HR=0.67), and overall survival (HR=0.65) in post-hoc analysis of archival samples from a Phase III clinical trial of clear cell renal cell carcinoma patients (PMID: 31486842). | 31486842 |
| PTEN dec exp | melanoma | decreased response | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Opdivo (nivolumab), as compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196). | 26645196 |
| PBRM1 inact mut | clear cell renal cell carcinoma | sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, renal clear cell carcinoma patients harboring PBRM1 loss-of-function mutations demonstrated improved response to immune checkpoint therapies including Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab), and Tecentriq (atezolizumab), potentially due to the distinct expression profile of immune-related genes in these patients (PMID: 29301960). | 29301960 |
| IDH1 wild-type PTEN mut | glioblastoma | resistant | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119). | 30742119 |
| MLH1 negative | ovarian carcinoma | predicted - sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial, Opdivo (nivolumab) treatment resulted in an objective response rate of 58.8% (20/34, 7 complete and 13 partial responses) and a progression-free survival rate at 24 mo of 64.7% in patients with MSI-high or deficient mismatch repair (dMMR defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) ovarian or endometrial carcinoma, including responses in 2 patients with uterine clear cell carcinoma and 1 patient with ovarian clear cell carcinoma (PMID: 38653864; NCT03241745). | 38653864 |
| FGFR3 mutant | transitional cell carcinoma | no benefit | Nivolumab | Phase II | Actionable | In a Phase II trial (CheckMate 275), Opdivo (nivolumab) (n=270) treatment resulted in similar response rate (20% vs 21%, p=0.2) in patients with FGFR3 mutant or wild-type metastatic transitional cell carcinoma (PMID: 31272788). | 31272788 |
| BRAF V600E | lung non-small cell carcinoma | not predictive | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, non-small cell lung cancer patients harboring BRAF V600E did not demonstrate a significantly different response to treatment with either Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), compared to patients with BRAF non-V600E mutations, demonstrating an objective response rate of 25% (3/12) vs 33% (3/9) (p=1.0) and median progression-free survival of 3.7 months vs 4.1 months (p=0.37) (PMID: 29723688). | 29723688 |
| BRAF wild-type | melanoma | predicted - sensitive | Nivolumab | Phase III | Actionable | In a Phase III trial (CheckMate-066), Opdivo (nivolumab) treatment resulted in improved overall survival and response compared to treatment with Deticene (dacarbazine) in melanoma patients with wild-type BRAF, including a 3-year overall survival (OS) rate of 51.2% vs. 21.6%, a median OS of 37.5 months vs. 11.2 months, a complete response in 19% (40/210) vs. 1.4% (3/208), and a partial response in 23.8% (50/210) vs. 13% (27/208), respectively (PMID: 30422243; NCT01721772). | 30422243 |
| MLH1 negative | endometrial carcinoma | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). | detail... |
| MLH1 negative | endometrial carcinoma | sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial, Opdivo (nivolumab) treatment resulted in an objective response rate of 58.8% (20/34, 7 complete and 13 partial responses) and a progression-free survival rate at 24 mo of 64.7% in patients with MSI-high or deficient mismatch repair (dMMR defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) ovarian or endometrial carcinoma, including responses in 2 patients with uterine clear cell carcinoma and 1 patient with ovarian clear cell carcinoma (PMID: 38653864; NCT03241745). | 38653864 |
| PTEN mutant | gastrointestinal system cancer | decreased response | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, patients with MSI high, dMMR gastrointestinal tumors including gastric (n=18), colorectal (n=17), cholangiocarcinoma (n=5), small intestine (n=2), pancreatic (n=2), and duodenal cancer (n=1) harboring PTEN mutations demonstrated a decreased objective response rate (21.4 vs 54.8%), overall survival (15.2 vs 25.7 mo), and progression-free survival (4.3 vs 15.6 mo) compared to PTEN-wild-type patients when treated with Keytruda (pembrolizumab) or Opdivo (nivolumab) (PMID: 33926917). | 33926917 |
| PBRM1 N463fs | clear cell renal cell carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in partial response in a patient with renal clear cell carcinoma harboring PBRM1 N463fs (PMID: 29301960). | 29301960 |
| MSH6 negative | colon cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 F1088Lfs*5 MSH6 Y1256* MSH6 A1320Sfs*5 | colorectal carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical case study, Opdivo (nivolumab) treatment resulted in stable disease lasting four months in a colorectal carcinoma patient harboring MSH6 F1088Lfs*5, Y1256*, and A1320Sfs*5 (PMID: 35739269). | 35739269 |
| MSH6 negative | colorectal cancer | sensitive | Nivolumab | FDA approved | Actionable | In a Phase II trial (CheckMate 142) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in an objective response rate of 36% (19/53, 1 complete response, 18 partial responses) and disease control for 12 weeks or more in 70% (37/53) of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 28734759; NCT02060188). | 28734759 detail... detail... |
| MSH6 negative | endometrial cancer | sensitive | Nivolumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | detail... 36696825 |
| MLH1 negative | rectum cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | cholangiocarcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), including 1 complete response and 1 stable disease in two patients with cholangiocarcinoma (PMID: 31765263; NCT02465060). | 31765263 |
| PBRM1 W141_L145delinsC | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 W141_L145delinsC (PMID: 29301960). | 29301960 |
| TP53 mutant | lung non-small cell carcinoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096). | 31097096 |
| BRAF mut IDH1 wild-type | glioblastoma | predicted - sensitive | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119). | 30742119 |
| PBRM1 Y331* | clear cell renal cell carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in complete response in a patient with renal clear cell carcinoma harboring PBRM1 Y331* (PMID: 29301960). | 29301960 |
| PBRM1 K135fs | clear cell renal cell carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in stable disease in a patient with renal clear cell carcinoma harboring PBRM1 K135fs (PMID: 29301960). | 29301960 |
| MLH1 negative | endometrial cancer | sensitive | Nivolumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Opdivo (nivolumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | detail... 36696825 |
| MLH1 negative | endometrial adenocarcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a Phase II trial (NCI-MATCH), Opdivo (nivolumab) treatment demonstrated preliminary efficacy in advanced solid tumor patients (excluding colorectal cancer) with deficient mismatch repair (defined by the loss of MLH1 or MSH2 expression by IHC), resulting in an objective response rate of 36% (15/42, 3 complete and 12 partial responses), including 2 complete responses and 2 partial responses in patients with endometrioid endometrial adenocarcinoma (n=13) (PMID: 31765263; NCT02465060). | 31765263 |
| PBRM1 R941fs | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 R941fs (PMID: 29301960). | 29301960 |
| MLH1 negative | colon cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | colorectal cancer | sensitive | Nivolumab | FDA approved | Actionable | In a Phase II trial (CheckMate 142) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in an objective response rate of 36% (19/53, 1 complete response, 18 partial responses) and disease control for 12 weeks or more in 70% (37/53) of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 28734759; NCT02060188). | detail... 28734759 detail... |
| MLH1 negative | small intestine adenocarcinoma | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | rectum cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PBRM1 N609fs | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 N609fs (PMID: 29301960). | 29301960 |
| MSH6 negative | ovarian carcinoma | predicted - sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial, Opdivo (nivolumab) treatment resulted in an objective response rate of 58.8% (20/34, 7 complete and 13 partial responses) and a progression-free survival rate at 24 mo of 64.7% in patients with MSI-high or deficient mismatch repair (dMMR defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) ovarian or endometrial carcinoma, including responses in 2 patients with uterine clear cell carcinoma and 1 patient with ovarian clear cell carcinoma (PMID: 38653864; NCT03241745). | 38653864 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03521830 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | Recruiting | USA | 0 |
| NCT02469701 | Phase II | Nivolumab | BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease | Terminated | USA | 0 |
| NCT04042753 | Phase II | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | Active, not recruiting | USA | 0 |
| NCT03465592 | Phase Ib/II | Nivolumab | Trial of Nivolumab Following Partially HLA Mismatched BMT in Children & Adults With Sarcoma | Recruiting | USA | 0 |
| NCT02038946 | Phase II | Nivolumab | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) | Completed | USA | SWE | NOR | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
| NCT02529072 | Phase I | Nivolumab | Nivolumab With DC Vaccines for Recurrent Brain Tumors | Completed | USA | 0 |
| NCT02017717 | Phase III | Nivolumab Bevacizumab Ipilimumab + Nivolumab | A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) | Completed | USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | BEL | AUS | 0 |
| NCT06275360 | Phase II | Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL) | Recruiting | USA | 0 |
| NCT03651271 | Phase II | Ipilimumab + Nivolumab Nivolumab | Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer | Completed | USA | 0 |
| NCT03727061 | Phase II | Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | Active, not recruiting | USA | 0 |
| NCT04567615 | Phase II | Nivolumab Nivolumab + Relatlimab | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | Active, not recruiting | TUR | ROU | POL | NZL | FRA | ESP | CZE | BRA | ARG | 8 |
| NCT03529890 | Phase II | Nivolumab | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder (RACE IT) | Unknown status | DEU | 0 |
| NCT02041533 | Phase III | Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Completed | USA | TUR | SWE | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
| NCT02837029 | Phase I | Nivolumab | Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer | Completed | USA | 0 |
| NCT05907122 | Phase III | Nivolumab | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Resected Melanoma | Recruiting | USA | ROU | NLD | ITA | HRV | FRA | ESP | DEU | BRA | ARG | 13 |
| NCT03838263 | Phase II | Nivolumab | Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer (IMMUNEBOOST) | Active, not recruiting | FRA | 0 |
| NCT06059547 | Phase II | Nivolumab CTL-002 + Nivolumab | Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer | Recruiting | ITA | 0 |
| NCT03685890 | Phase Ib/II | Nivolumab | Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (NivoILP) | Recruiting | SWE | NLD | 0 |
| NCT02574078 | Phase Ib/II | Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) | Completed | USA | 0 |
| NCT05002569 | Phase III | Nivolumab + Relatlimab Nivolumab | A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098) | Active, not recruiting | USA | SWE | ROU | NOR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
| NCT04929041 | Phase II | Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin | Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | Recruiting | USA | 0 |
| NCT03090737 | Phase II | Nivolumab | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907) | Completed | USA | ROU | CAN | 2 |
| NCT04019964 | Phase II | Nivolumab | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | Recruiting | USA | 0 |
| NCT03038672 | Phase II | Nivolumab + Varlilumab Nivolumab | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | Active, not recruiting | USA | 0 |
| NCT03143270 | Phase I | Nivolumab | A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer | Active, not recruiting | USA | 0 |
| NCT04581382 | Phase I | Pembrolizumab Nivolumab | Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | Active, not recruiting | USA | 0 |
| NCT02428192 | Phase II | Nivolumab | Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma | Active, not recruiting | USA | 0 |
| NCT03521570 | Phase II | Nivolumab | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer | Completed | USA | 0 |
| NCT03468985 | Phase II | Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | Completed | USA | 0 |
| NCT02840994 | Phase Ib/II | CV301 + Nivolumab Nivolumab | A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT03520491 | Phase II | Ipilimumab + Nivolumab Nivolumab | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | Recruiting | USA | 0 |
| NCT02530463 | Phase II | Nivolumab Azacitidine Ipilimumab | Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Active, not recruiting | USA | 0 |
| NCT03222076 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) | Completed | USA | 0 |
| NCT03878979 | Phase II | Nivolumab | Preoperative Immune Checkpoint Inhibitor for Patients With Recurrent or Metastatic SCCHN Undergoing Surgical Salvage | Completed | USA | 0 |
| NCT04322643 | Phase II | Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Completed | USA | 0 |
| NCT02339571 | Phase II | Sargramostim Nivolumab Ipilimumab | Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
| NCT03817125 | Phase I | Nivolumab + SER-401 Vancomycin Nivolumab | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) | Completed | USA | 0 |
| NCT03371992 | Phase I | Nivolumab | Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL) | Unknown status | USA | 0 |
| NCT03576612 | Phase I | AdV-tk Temozolomide Valacyclovir Nivolumab | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas (GMCI) | Active, not recruiting | USA | 0 |
| NCT04007588 | Phase II | Ipilimumab + Nivolumab Nivolumab Linrodostat + Nivolumab | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | Withdrawn | USA | 0 |
| NCT02500797 | Phase II | Ipilimumab Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma | Completed | USA | 0 |
| NCT03068455 | Phase III | Nivolumab Ipilimumab Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) | Completed | USA | ROU | POL | NZL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 1 |
| NCT04697576 | Phase I | Nivolumab Pembrolizumab Ipilimumab | Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma | Recruiting | USA | 0 |
| NCT01658878 | Phase I | Nivolumab | Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | 6 |
| NCT03712202 | Phase II | Nivolumab Brentuximab vedotin + Nivolumab Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine | Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
| NCT03918252 | Phase II | Ipilimumab + Nivolumab Nivolumab | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | Active, not recruiting | USA | 0 |
| NCT03382912 | Phase II | Nivolumab + Pegilodecakin Nivolumab | Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2) | Terminated | USA | 0 |
| NCT03631641 | Phase II | Nivolumab | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy | Terminated | USA | 0 |
| NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
| NCT02781506 | Phase II | Nivolumab | Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer | Terminated | USA | 0 |
| NCT02599649 | Phase II | Nivolumab Azacitidine Lirilumab | Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Terminated | USA | 0 |
| NCT04526730 | Phase II | Nivolumab + Tavokinogene telseplasmid Nivolumab | Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients | Active, not recruiting | USA | 0 |
| NCT02532231 | Phase II | Nivolumab | Nivolumab in AML in Remission at High Risk for Relapse | Completed | USA | 0 |
| NCT05148546 | Phase II | Ipilimumab + Nivolumab Nivolumab Nivolumab + Relatlimab | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO) | Recruiting | NLD | GBR | 0 |
| NCT03812562 | Phase I | Nivolumab | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | Terminated | USA | 0 |
| NCT03959761 | Phase Ib/II | Nivolumab | Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (ICONIC) | Unknown status | FRA | 0 |
| NCT03532451 | Phase I | Lirilumab + Nivolumab Nivolumab | Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807) | Completed | USA | 0 |
| NCT02142218 | Phase I | Nivolumab | Expanded Access Program With Nivolumab to Treat Melanoma | No longer available | USA | CAN | BRA | ARG | 2 |
| NCT03715946 | Phase II | Nivolumab | Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | Active, not recruiting | USA | 0 |
| NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
| NCT02737475 | Phase Ib/II | Ipilimumab BMS-986178 Nivolumab | Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | ITA | ISR | ESP | CAN | 0 |
| NCT02210117 | Phase II | Nivolumab Bevacizumab + Nivolumab Ipilimumab + Nivolumab | Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) | Active, not recruiting | USA | 0 |
| NCT05297565 | Phase III | Nivolumab BMS-986298 | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (CheckMate-6GE) | Completed | USA | POL | ITA | GBR | ESP | BEL | AUS | 0 |
| NCT03023904 | Phase II | Nivolumab | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | Withdrawn | 0 | |
| NCT03980041 | Phase II | Nivolumab Eganelisib + Nivolumab | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | Completed | USA | POL | ITA | FRA | ESP | CZE | 1 |
| NCT03798639 | Phase I | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | Completed | USA | 0 |
| NCT04323046 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Recruiting | USA | ISR | CHE | AUS | 0 |
| NCT03168464 | Phase Ib/II | Nivolumab | Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) | Terminated | USA | 0 |
| NCT03149120 | Phase II | Nivolumab Nivolumab + Pazopanib | Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | Withdrawn | USA | 0 |
| NCT03313804 | Phase II | Pembrolizumab Atezolizumab Nivolumab | Priming Immunotherapy in Advanced Disease With Radiation | Active, not recruiting | USA | 0 |
| NCT05504252 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Nivolumab | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (METIMMOX-2) | Recruiting | NOR | 0 |
| NCT04801966 | Phase 0 | Palbociclib Alpelisib Atezolizumab Vemurafenib Ribociclib Talazoparib Cobimetinib Trametinib Abemaciclib Dabrafenib Nivolumab Binimetinib Pembrolizumab Encorafenib | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR) | Terminated | AUS | 0 |
| NCT03371381 | Phase Ib/II | JNJ-64041757 + Nivolumab Nivolumab | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | Terminated | USA | ESP | BEL | 0 |
| NCT03522246 | Phase III | Rucaparib Nivolumab Nivolumab + Rucaparib | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NZL | ITA | ISR | IRL | GRC | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 5 |
| NCT06523621 | Phase II | Nivolumab | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | Not yet recruiting | USA | 0 |
| NCT02259621 | Phase II | Nivolumab | Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC | Active, not recruiting | USA | CAN | 0 |
| NCT03302247 | Phase II | Nivolumab Gemcitabine + Nivolumab | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | Terminated | USA | 0 |
| NCT03461952 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe) | Terminated | USA | CAN | 0 |
| NCT03850067 | Phase Ib/II | Carboplatin + CC-90011 + Etoposide CC-90011 + Cisplatin + Etoposide Nivolumab | A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer | Completed | ITA | FRA | ESP | 0 |
| NCT04340193 | Phase III | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) | Terminated | USA | POL | ITA | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 8 |
| NCT02632409 | Phase III | Nivolumab | A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma | Active, not recruiting | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT02275533 | Phase II | Nivolumab | Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy | Active, not recruiting | USA | CAN | 0 |
| NCT02339558 | Phase II | Nivolumab | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | Completed | USA | 2 |
| NCT03115801 | Phase II | Atezolizumab Nivolumab | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | Terminated | USA | 0 |
| NCT05111574 | Phase II | Nivolumab Cabozantinib + Nivolumab | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | Recruiting | USA | CAN | 0 |
| NCT04401995 | Phase II | Nivolumab Nivolumab + Vidutolimod | Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab | Completed | USA | 0 |
| NCT04957615 | Phase II | Nivolumab | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression | Recruiting | USA | 0 |
| NCT02775292 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine Nivolumab NY-ESO-1 peptide vaccine | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | Completed | USA | 0 |
| NCT04157985 | Phase III | Nivolumab Ipilimumab Pembrolizumab Atezolizumab | Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05112601 | Phase II | Ipilimumab + Nivolumab Nivolumab | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Recruiting | USA | 0 |
| NCT02156804 | Phase II | Nivolumab | A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) | Completed | SWE | ROU | POL | NOR | NLD | LUX | ITA | IRL | HUN | GRC | GBR | FIN | ESP | DEU | CZE | CHE | BEL | AUT | 2 |
| NCT03776487 | Phase Ib/II | Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | Active, not recruiting | USA | 0 |
| NCT03690986 | Phase I | Ipilimumab Nivolumab Ipilimumab + Pepinemab Nivolumab + Pepinemab Pepinemab | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | Recruiting | USA | 0 |
| NCT02060188 | Phase Ib/II | Nivolumab Ipilimumab | A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) | Active, not recruiting | USA | ITA | IRL | FRA | ESP | CAN | BEL | AUS | 0 |
| NCT04268888 | Phase II | Nivolumab | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3) | Recruiting | GBR | 0 |
| NCT04026412 | Phase III | Nivolumab Ipilimumab + Nivolumab Durvalumab | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | Active, not recruiting | USA | SWE | ROU | POL | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUS | ARG | 9 |
| NCT04953104 | Phase II | Nivolumab | Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression | Recruiting | USA | 0 |
| NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Completed | USA | 0 |
| NCT03383458 | Phase III | Nivolumab | A Phase 3 Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Active, not recruiting | USA | ROU | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
| NCT04495010 | Phase II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) | Withdrawn | USA | SWE | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | 1 |
| NCT04637594 | Phase III | Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Active, not recruiting | USA | 0 |
| NCT04050462 | Phase II | BMS-986253 + Nivolumab Nivolumab Cabiralizumab + Nivolumab | A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients | Active, not recruiting | USA | 0 |
| NCT03630640 | Phase II | Nivolumab | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP) | Completed | FRA | 0 |
| NCT03844256 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (CRIMI) | Recruiting | NLD | 0 |
| NCT04401774 | Phase II | Nivolumab | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | Active, not recruiting | USA | 0 |
| NCT02477826 | Phase III | Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine | An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | ROU | POL | NLD | LBN | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
| NCT02720484 | Phase II | Nivolumab | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | Terminated | USA | 0 |
| NCT03807765 | Phase I | Nivolumab | Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases | Active, not recruiting | USA | 0 |
| NCT02829918 | Phase II | Nivolumab | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers | Completed | USA | 0 |
| NCT03215810 | Phase I | Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT02989636 | Phase I | Nivolumab | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma | Active, not recruiting | USA | 0 |
| NCT04620200 | Phase II | Ipilimumab + Nivolumab Nivolumab | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE) | Unknown status | NLD | 0 |
| NCT06116461 | FDA approved | Nivolumab | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NIVOPTIMIZE) | Recruiting | NLD | 0 |
| NCT02652455 | Phase I | Nivolumab Aldesleukin + Cyclophosphamide + Fludarabine Urelumab | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | Completed | USA | 0 |
| NCT04013854 | Phase II | Ipilimumab + Nivolumab Nivolumab | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | Active, not recruiting | USA | 0 |
| NCT03355560 | Phase II | Nivolumab | Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy | Active, not recruiting | USA | 0 |
| NCT04594811 | Phase II | Nivolumab Nivolumab + NT-I7 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | Terminated | USA | POL | 0 |
| NCT03367741 | Phase II | Cabozantinib + Nivolumab Nivolumab | Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT06064097 | Phase II | Nivolumab Cisplatin + Nivolumab Cisplatin + Gemcitabine + Nivolumab | A Study Using a New Drug, Nivolumab, in Combination With Chemotherapy Drugs to Treat a Type of Cancer Called Nasopharyngeal Carcinoma (NPC) | Recruiting | USA | 0 |
| NCT03899155 | FDA approved | Nivolumab | Pan Tumor Nivolumab Rollover Study | Recruiting | USA | TUR | SWE | ROU | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
| NCT05817903 | Phase II | Nivolumab Axitinib + Nivolumab | Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous CR (AxIn) | Recruiting | ITA | 0 |
| NCT04810078 | Phase III | Nivolumab Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T) | Recruiting | USA | TUR | ROU | POL | NZL | ITA | IRL | FRA | FIN | ESP | CZE | BRA | ARG | 4 |
| NCT03316274 | Phase I | Nivolumab | Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma | Completed | USA | 0 |
| NCT03405155 | Phase II | Nivolumab | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT03233711 | Phase II | Nivolumab | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT02498600 | Phase II | Ipilimumab Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
| NCT03635983 | Phase III | Nivolumab Nivolumab + NKTR-214 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | Completed | USA | SWE | ROU | POL | NZL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
| NCT02857426 | Phase II | Nivolumab | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647) | Completed | USA | ITA | ISR | HUN | FRA | DEU | CZE | CAN | BRA | 4 |
| NCT03604978 | Phase Ib/II | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III Meningioma | Recruiting | USA | 0 |
| NCT02897765 | Phase I | Nivolumab NEO-PV-01 + Poly ICLC | A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | Completed | USA | 0 |
| NCT03241745 | Phase II | Nivolumab | A Study of Nivolumab in Selected Uterine Cancer Patients | Completed | USA | 0 |
| NCT03873402 | Phase III | Nivolumab Ipilimumab + Nivolumab | An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Active, not recruiting | USA | ROU | POL | ITA | GRC | FRA | ESP | CZE | AUT | ARG | 4 |
| NCT02423343 | Phase Ib/II | Galunisertib Nivolumab | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma | Completed | USA | ESP | 0 |
| NCT02631746 | Phase II | Nivolumab | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | Completed | USA | 0 |
| NCT04090710 | Phase II | Nivolumab Ipilimumab + Nivolumab | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) | Active, not recruiting | CAN | AUS | 0 |
| NCT03879811 | Phase II | Nivolumab Temozolomide | Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer | Withdrawn | 0 | |
| NCT03906526 | Phase I | Motolimod Motolimod + Nivolumab Nivolumab | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | Terminated | USA | 0 |
| NCT02978404 | Phase II | Nivolumab | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | Completed | CAN | 0 |
| NCT02519322 | Phase II | Ipilimumab Nivolumab | Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma | Completed | USA | 0 |
| NCT02483247 | Phase Ib/II | Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Completed | USA | CAN | 0 |
| NCT04080804 | Phase II | Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | Recruiting | USA | 0 |
| NCT02664181 | Phase II | Nivolumab Decitabine + Nivolumab + Tetrahydrouridine | Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE) | Completed | USA | 0 |
| NCT06101134 | Phase II | BMS-986298 Nivolumab + Relatlimab + rHuPH20 Nivolumab and relatlimab-rmbw Nivolumab | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | Recruiting | USA | ITA | GRC | ESP | ARG | 1 |
| NCT02105636 | Phase III | Methotrexate Cetuximab Docetaxel Nivolumab | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BRA | ARG | 4 |
| NCT03557359 | Phase II | Nivolumab | Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | Active, not recruiting | USA | 0 |
| NCT02992964 | Phase Ib/II | Nivolumab | Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers | Terminated | USA | ISR | FRA | CAN | AUS | 0 |
| NCT03021993 | Phase II | Nivolumab | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | Completed | USA | 0 |
| NCT05496192 | Phase II | Nivolumab BMS-986298 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | Withdrawn | ESP | DEU | 0 |
| NCT02259231 | Phase Ib/II | Ipilimumab Nivolumab Omaveloxolone | RTA 408 Capsules in Patients With Melanoma - REVEAL | Completed | USA | 0 |
| NCT03663166 | Phase Ib/II | Cisplatin + Ipilimumab + Pemetrexed Disodium Nivolumab Carboplatin + Ipilimumab + Paclitaxel Cisplatin + Etoposide + Ipilimumab | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
| NCT02553642 | Phase II | Nivolumab Ipilimumab | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | Completed | USA | 0 |
| NCT02387996 | Phase II | Nivolumab | A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer | Completed | USA | SWE | POL | ITA | FIN | ESP | DEU | CZE | BEL | AUS | 1 |
| NCT04042506 | Phase II | Nivolumab | SBRT as a Vaccination for Metastatic Melanoma | Withdrawn | USA | 0 |
| NCT03704077 | Phase II | Nivolumab Paclitaxel + Ramucirumab Nivolumab + Paclitaxel Nivolumab + Paclitaxel + Relatlimab Nivolumab + Relatlimab | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma | Withdrawn | USA | ROU | ITA | ESP | DEU | CAN | BRA | AUS | ARG | 5 |
| NCT06534983 | Phase II | Nivolumab Autogene cevumeran + Nivolumab | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) (IMCODE004) | Recruiting | USA | ITA | DEU | CAN | AUS | 0 |
| NCT05491616 | Phase II | Nivolumab | Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study (SANO-3) | Recruiting | NLD | 0 |
| NCT04128020 | Phase I | Azacitidine + Nivolumab Nivolumab | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | Withdrawn | 0 | |
| NCT03238365 | Phase I | Nivolumab + Tadalafil Nivolumab | Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Completed | USA | 0 |
| NCT03703050 | Phase II | Nivolumab | Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL) | Recruiting | NLD | FRA | DNK | 0 |
| NCT02596035 | FDA approved | Nivolumab | A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) | Completed | USA | 0 |
| NCT02614456 | Phase I | Nivolumab Interferon gamma | Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors | Completed | USA | 0 |
| NCT02823574 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | TUR | SWE | ROU | NOR | NLD | ITA | IRL | GBR | FRA | FIN | ESP | CZE | CAN | BRA | BEL | ARG | 4 |
| NCT02716948 | Phase I | Nivolumab | Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | Completed | USA | 0 |
| NCT06112314 | Phase III | Nivolumab IMC-F106C + Nivolumab Nivolumab + Relatlimab | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301) | Recruiting | USA | SWE | ROU | POL | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | BGR | AUT | AUS | ARG | 0 |
| NCT06319196 | Phase II | Nivolumab Nivolumab and relatlimab-rmbw | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe) | Recruiting | CAN | 0 |
| NCT03718767 | Phase II | Nivolumab | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | Recruiting | USA | 0 |
| NCT03335540 | Phase I | Linrodostat + Nivolumab Nivolumab + Relatlimab Cabiralizumab + Nivolumab Lirilumab + Nivolumab BMS-986156 + Nivolumab Ipilimumab + Nivolumab Nivolumab | An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | Completed | USA | 0 |
| NCT03432741 | Phase I | Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Suspended | USA | 0 |
| NCT03803553 | Phase III | Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | Recruiting | USA | 0 |
| NCT05150236 | Phase II | Ipilimumab + lutetium Lu 177 vipivotide tetraxetan + Nivolumab lutetium Lu 177 vipivotide tetraxetan Nivolumab | 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION) (EVOLUTION) | Active, not recruiting | AUS | 0 |
| NCT04758949 | Phase II | Nivolumab FL-101 + Nivolumab FL-101 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Withdrawn | 0 | |
| NCT03025256 | Phase I | Nivolumab | Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD) | Recruiting | USA | 0 |
| NCT03258567 | Phase II | Nivolumab | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | Recruiting | USA | 0 |
| NCT03980314 | Phase Ib/II | Nivolumab | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | Completed | USA | ROU | POL | NZL | ITA | IRL | FRA | ESP | CAN | BRA | AUS | ARG | 2 |
| NCT03487666 | Phase II | Capecitabine + Nivolumab Capecitabine Nivolumab | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | Active, not recruiting | USA | 0 |
| NCT02451982 | Phase Ib/II | Nivolumab Cyclophosphamide + GVAX pancreatic cancer vaccine | Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer | Recruiting | USA | 0 |
| NCT03171025 | Phase II | Nivolumab | Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT) | Active, not recruiting | USA | 0 |
| NCT02439450 | Phase I | HS-110 Nivolumab | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT03508570 | Phase I | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Active, not recruiting | USA | 0 |
| NCT02575222 | Phase I | Nivolumab | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | Completed | USA | 0 |
| NCT01585194 | Phase II | Ipilimumab Nivolumab | Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma | Completed | USA | 0 |
| NCT03406247 | Phase II | Ipilimumab + Nivolumab Nivolumab | Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1) | Recruiting | FRA | 0 |
| NCT02726581 | Phase III | Elotuzumab Nivolumab Dexamethasone + Pomalidomide | Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma | Completed | USA | TUR | SWE | NOR | ITA | ISR | GRC | ESP | DNK | DEU | CZE | CHE | CAN | AUT | 2 |
| NCT03130959 | Phase II | Ipilimumab + Nivolumab Nivolumab | An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) | Completed | USA | SWE | POL | NOR | NLD | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 2 |
| NCT03107182 | Phase II | Dexamethasone + Diphenhydramine + Famotidine + Fluorouracil + Hydroxyurea + Paclitaxel Carboplatin + Nab-paclitaxel + Nivolumab Cisplatin Carboplatin + Nivolumab + Paclitaxel Nivolumab | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer (OPTIMA-II) | Completed | USA | 0 |
| NCT03126331 | Phase II | Nivolumab | Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients | Completed | USA | 0 |
| NCT02598960 | Phase Ib/II | Nivolumab BMS-986156 | A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | ITA | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 0 |
| NCT03743766 | Phase II | Relatlimab Nivolumab + Relatlimab Nivolumab | Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | Completed | USA | 0 |
| NCT02518958 | Phase I | Nivolumab | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab | Completed | USA | 0 |
| NCT02475382 | Expanded access | Nivolumab | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169) | No longer available | CAN | BRA | 0 |
| NCT02569242 | Phase III | Docetaxel + Paclitaxel Nivolumab | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | Completed | USA | ITA | GBR | DNK | DEU | 3 |
| NCT04500548 | Phase I | Nivolumab Ipilimumab + Nivolumab | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | Withdrawn | USA | CAN | 0 |
| NCT02764593 | Phase I | Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab | Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT05846646 | Phase II | Pembrolizumab Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | Terminated | USA | 0 |
| NCT03166397 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab tumor infiltrating lymphocytes Ipilimumab | Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | Recruiting | ISR | 0 |
| NCT04204837 | Phase II | Nivolumab + Relatlimab Nivolumab | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | Recruiting | AUT | 0 |
| NCT04866654 | Phase II | Nivolumab | Radiation Free Chemotherapy for Early Hodgkin Lymphoma (RAFTING) | Recruiting | POL | ITA | ESP | 0 |
| NCT04173325 | Phase I | Nivolumab Irinotecan + Nivolumab | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Terminated | USA | 0 |
| NCT04901988 | Phase II | Nivolumab | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION) | Terminated | GBR | 0 |
| NCT03544723 | Phase II | Nivolumab Ad5CMV-p53 gene + Nivolumab | Safety and Efficacy of Ad-p53 in Head and Neck Cancer | Unknown status | USA | 0 |
| NCT06237920 | Phase II | Nivolumab Nivolumab + Relatlimab | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab (TURANDORELA) | Recruiting | NLD | 0 |
| NCT02736123 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | Withdrawn | USA | 0 |
| NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | GBR | FIN | ESP | DNK | DEU | CAN | 0 |
| NCT01621490 | Phase I | Ipilimumab Nivolumab | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) | Completed | USA | NLD | ESP | 0 |
| NCT03572478 | Phase Ib/II | Nivolumab + Rucaparib Nivolumab Rucaparib | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Terminated | USA | 0 |
| NCT02914405 | Phase I | Dinutuximab beta + Nivolumab Nivolumab | Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma (MiniVan) | Recruiting | USA | GBR | 0 |
| NCT01928576 | Phase II | Nivolumab Entinostat Azacitidine | Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. | Completed | USA | 0 |
| NCT02832167 | Phase II | Nivolumab | An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread (CheckMate 627) | Completed | USA | DEU | 0 |
| NCT04008030 | Phase III | Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) | Recruiting | USA | TUR | ROU | NOR | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
| NCT04612530 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Nivolumab IMO-2125 + Nivolumab | PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | Recruiting | NLD | 0 |
| NCT03470922 | Phase II | Nivolumab + Relatlimab Nivolumab | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | Active, not recruiting | USA | SWE | ROU | POL | NZL | NOR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
| NCT04123379 | Phase II | BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
| NCT04658147 | Phase I | Nivolumab + Relatlimab Nivolumab | Feasibility and Efficacy of Perioperative Nivolumab With or Without Neoadjuvant Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | Recruiting | USA | 0 |
| NCT02314169 | Phase II | Nivolumab | Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal | Active, not recruiting | USA | CAN | 0 |
| NCT04387084 | Phase I | Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | Active, not recruiting | USA | 0 |
| NCT03768531 | Phase II | Cabiralizumab + Nivolumab Nivolumab | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | Withdrawn | 0 | |
| NCT04620603 | Phase Ib/II | Nivolumab | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | Recruiting | USA | 0 |
| NCT06295159 | Phase I | Nivolumab Nivolumab and relatlimab-rmbw Ipilimumab + Nivolumab | Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | Recruiting | USA | 0 |
| NCT04929028 | Phase II | Capecitabine + Mitomycin C Nivolumab Fluorouracil + Mitomycin C | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Recruiting | USA | 0 |
| NCT03421652 | Phase II | Nivolumab | Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy | Completed | USA | 0 |
| NCT04913025 | Phase II | Pembrolizumab Nivolumab | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) | Recruiting | GBR | 0 |
| NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
| NCT04462406 | Phase II | Pembrolizumab Nivolumab + Pembrolizumab Ipilimumab + Nivolumab Ipilimumab + Pembrolizumab Nivolumab | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | Recruiting | USA | 0 |
| NCT04949113 | Phase III | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA) | Active, not recruiting | USA | NLD | AUS | 0 |
| NCT06264180 | Phase III | Nab-paclitaxel Nivolumab + RP1 Paclitaxel Nivolumab and relatlimab-rmbw Nivolumab Dacarbazine Pembrolizumab Temozolomide | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) | Recruiting | USA | 0 |
| NCT02750514 | Phase II | Dasatinib + Nivolumab Nivolumab + Relatlimab Nivolumab Linrodostat + Nivolumab | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) | Terminated | USA | ITA | FRA | ESP | CHE | CAN | AUT | AUS | 0 |
| NCT02257528 | Phase II | Nivolumab | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | Active, not recruiting | USA | 0 |
| NCT03122522 | Phase II | Nivolumab Ipilimumab + Nivolumab | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | Active, not recruiting | USA | 0 |
| NCT04606316 | Phase I | Nivolumab Ipilimumab + Nivolumab | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Active, not recruiting | USA | 0 |
| NCT06410534 | Phase II | Nivolumab Ipilimumab + Nivolumab | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer | Recruiting | USA | 0 |
| NCT04209114 | Phase III | Nivolumab + NKTR-214 Nivolumab | A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer. | Completed | USA | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
| NCT01176474 | Phase I | NY-ESO-1 peptide vaccine Ipilimumab Nivolumab | A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | Completed | USA | 0 |
| NCT05465174 | Phase II | Nivolumab + Tovorafenib Tovorafenib Nivolumab | Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults (PNOC029) | Recruiting | USA | 0 |
| NCT03600155 | Phase I | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT03595124 | Phase II | Nivolumab Axitinib + Nivolumab Axitinib | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | Active, not recruiting | USA | 1 |
| NCT03656627 | Phase I | Nivolumab | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | Terminated | USA | 0 |
| NCT04309409 | Phase III | Nivolumab | Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma (NivoMela) | Active, not recruiting | DEU | 0 |
| NCT03539198 | Phase 0 | Nivolumab | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | Terminated | USA | 0 |
| NCT02565758 | Phase I | Gemcitabine Nivolumab Nab-paclitaxel ABBV-085 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors | Completed | USA | FRA | ESP | 0 |
| NCT04875611 | Phase II | Nivolumab | Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment (NIVONASO-21) | Not yet recruiting | POL | 0 |
| NCT03496662 | Phase Ib/II | Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | Completed | USA | 0 |
| NCT03259867 | Phase II | Nivolumab Pembrolizumab | Combination of TATE and PD-1 Inhibitor in Liver Cancer | Recruiting | USA | 0 |
| NCT03430791 | Phase II | Ipilimumab + Nivolumab Nivolumab | Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | Terminated | USA | 0 |
| NCT02595918 | Phase I | Nivolumab | Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer | Terminated | USA | 0 |
| NCT04400539 | Phase II | Nivolumab | The IMmunotherapy Pleural 5-ALA PDT (IMPALA) | Recruiting | FRA | 0 |
| NCT04295863 | Phase I | Nivolumab Pembrolizumab | Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers | Recruiting | USA | 0 |
| NCT03106610 | Phase I | Nivolumab | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | Terminated | USA | 0 |
| NCT05743270 | Phase II | Cisplatin Nivolumab Cisplatin + RP3 Carboplatin + Paclitaxel + RP3 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Withdrawn | USA | POL | GRC | GBR | FRA | ESP | DEU | CZE | 0 |
| NCT04695977 | Phase II | Nivolumab Nivolumab + Vidutolimod | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | Terminated | USA | 0 |
| NCT02426892 | Phase II | Nivolumab | Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | Completed | USA | 0 |
| NCT03495713 | Phase II | Nivolumab | RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS | Terminated | USA | 0 |
| NCT02472977 | Phase Ib/II | Nivolumab Ulocuplumab | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors | Terminated | USA | FIN | 0 |
| NCT03591731 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC) | Active, not recruiting | FRA | 0 |
| NCT05652673 | FDA approved | Nivolumab | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | Recruiting | NLD | 0 |
| NCT03634800 | Phase II | Nivolumab | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M) | Terminated | USA | 0 |
| NCT03743662 | Phase II | Nivolumab Bevacizumab | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | Active, not recruiting | USA | 0 |
| NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Recruiting | USA | 0 |
| NCT03075553 | Phase II | Nivolumab | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Terminated | USA | 0 |
| NCT02696993 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT03307616 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
| NCT04134325 | Phase I | Nivolumab Pembrolizumab | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
| NCT03117309 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | Unknown status | USA | 0 |
| NCT05987241 | Phase II | Nivolumab Nivolumab + Relatlimab | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study | Recruiting | USA | 0 |
| NCT03203304 | Phase I | Nivolumab Ipilimumab + Nivolumab | Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma | Terminated | USA | 0 |
| NCT02423954 | Phase Ib/II | Temsirolimus Nivolumab Capecitabine Irinotecan | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | Terminated | USA | 0 |
| NCT04648319 | Phase II | Nivolumab | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Terminated | LUX | LBN | BEL | 0 |
| NCT02576509 | Phase III | Nivolumab Sorafenib | A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma | Completed | USA | SWE | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 7 |
| NCT03355976 | Phase II | Ipilimumab + Nivolumab Nivolumab | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | Active, not recruiting | USA | 0 |
| NCT02919683 | Phase II | Nivolumab Ipilimumab + Nivolumab | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | Active, not recruiting | USA | 0 |
| NCT02648997 | Phase II | Nivolumab | A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma | Active, not recruiting | USA | 0 |
| NCT02967133 | Phase II | Nab-paclitaxel + Nivolumab Nivolumab | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | Terminated | USA | 0 |
| NCT02488759 | Phase Ib/II | Nivolumab | A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) | Completed | USA | NLD | GBR | FRA | ESP | DEU | BEL | 4 |
| NCT03158129 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection | Active, not recruiting | USA | 0 |
| NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Terminated | USA | 0 |
| NCT03055013 | Phase III | Nivolumab | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER) | Active, not recruiting | USA | ISR | CAN | 0 |
| NCT03121417 | Phase II | Nivolumab | Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer | Withdrawn | USA | 0 |
| NCT03285321 | Phase II | Ipilimumab + Nivolumab Nivolumab | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
| NCT03793166 | Phase III | Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab | Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer | Active, not recruiting | USA | 1 |
| NCT02785952 | Phase III | Nivolumab Ipilimumab + Nivolumab | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | Active, not recruiting | USA | CAN | 0 |
| NCT04361058 | Phase I | Nivolumab | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | Withdrawn | USA | 0 |
| NCT02864381 | Phase II | Nivolumab Andecaliximab + Nivolumab | GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | BEL | AUS | 0 |
| NCT02962804 | Phase II | Nivolumab | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | Withdrawn | USA | 0 |
| NCT02595944 | Phase III | Nivolumab | Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) | Active, not recruiting | USA | 0 |
| NCT03317327 | Phase Ib/II | Nivolumab | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT) | Recruiting | NOR | 0 |
| NCT02481830 | Phase III | Amrubicin Nivolumab Topotecan | Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer | Completed | USA | ROU | POL | NOR | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | BRA | BEL | AUT | AUS | 6 |
| NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |
| NCT02388906 | Phase III | Nivolumab Ipilimumab | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) | Active, not recruiting | USA | SWE | ROU | POL | NOR | NLD | ITA | IRL | HUN | GRC | GBR | FRA | FIN | ESP | CZE | CHE | CAN | BEL | AUT | AUS | ARG | 4 |
| NCT03527108 | Phase II | Nivolumab + Ramucirumab Nivolumab | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | Recruiting | USA | 0 |
| NCT03854032 | Phase II | Nivolumab Linrodostat + Nivolumab | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | Terminated | USA | 0 |
| NCT02924233 | Phase Ib/II | Nivolumab + SYM004 Nivolumab | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | Withdrawn | 0 | |
| NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | 0 |
| NCT04149275 | Phase II | Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma | Withdrawn | USA | 0 |
| NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
| NCT03080974 | Phase II | Nivolumab | Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
| NCT02684253 | Phase II | Nivolumab | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | Completed | USA | 0 |
| NCT04410445 | Phase III | Nivolumab Nivolumab + NKTR-214 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) | Terminated | USA | ROU | POL | NZL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | AUT | AUS | 2 |
| NCT05188118 | Phase I | Cabozantinib Nivolumab Everolimus Ipilimumab Lenvatinib | Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |
| NCT03543189 | Phase Ib/II | Nivolumab | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | Active, not recruiting | USA | 0 |
| NCT03770299 | Phase II | Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) | Withdrawn | 0 | |
| NCT03610711 | Phase Ib/II | Nivolumab + Relatlimab Nivolumab | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) | Active, not recruiting | USA | 0 |
| NCT05112549 | Phase I | Nivolumab | Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) (IT-PD1) | Recruiting | DEU | 0 |
| NCT03604991 | Phase II | Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab | Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma | Suspended | USA | 0 |
| NCT03952585 | Phase II | Nivolumab Cisplatin | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT02066636 | Phase III | Nivolumab | A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153) | Completed | USA | CAN | 0 |
| NCT02599402 | Phase III | Ipilimumab + Nivolumab Nivolumab | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | Completed | SWE | NOR | ITA | IRL | GBR | FRA | FIN | DEU | CHE | BEL | AUT | AUS | 0 |
| NCT05317000 | Phase I | Azacitidine Azacitidine + Nivolumab Nivolumab | 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC | Recruiting | USA | 0 |
| NCT04013542 | Phase I | Ipilimumab + Nivolumab Nivolumab | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | Active, not recruiting | USA | 0 |
| NCT04021420 | Phase Ib/II | Nivolumab | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (SONIMEL01) | Unknown status | FRA | 0 |
| NCT03195491 | Phase III | Nivolumab | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870) | Completed | 2 | |
| NCT03203473 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | Active, not recruiting | USA | 0 |
| NCT02731729 | Phase II | Ipilimumab Nivolumab | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | Completed | USA | 0 |
| NCT03425292 | Phase I | Temozolomide Ipilimumab + Nivolumab Nivolumab | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | Completed | USA | 0 |
| NCT03383302 | Phase Ib/II | Nivolumab | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE) | Active, not recruiting | GBR | 0 |
| NCT02421354 | Phase II | Nivolumab | Study of Nivolumab in Patients With Myelofibrosis | Terminated | USA | 0 |
| NCT02538666 | Phase III | Ipilimumab Nivolumab | A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) | Completed | USA | SWE | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
| NCT02311920 | Phase I | Temozolomide Nivolumab Ipilimumab | Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Completed | USA | 0 |
| NCT02829931 | Phase I | Nivolumab | Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas | Completed | USA | 0 |
| NCT04674683 | Phase III | Nivolumab Chidamide + Nivolumab | Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma | Active, not recruiting | USA | NZL | ITA | GBR | FRA | ESP | DEU | CZE | BRA | BEL | AUT | AUS | 5 |
| NCT06029270 | Phase II | Carboplatin + Gemcitabine + Nivolumab Nivolumab Nivolumab + Relatlimab Cisplatin + Gemcitabine + Nivolumab | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | Recruiting | USA | CAN | 2 |
| NCT02181738 | Phase II | Nivolumab | Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205) | Completed | USA | NLD | ITA | GBR | ESP | DEU | CZE | CAN | BEL | AUT | 0 |
| NCT03110978 | Phase II | Nivolumab | Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR | Active, not recruiting | USA | 0 |
| NCT04205552 | Phase II | Nivolumab + Relatlimab Nivolumab | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict) | Recruiting | NLD | DEU | BEL | 0 |
| NCT03247712 | Phase Ib/II | Nivolumab | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | Active, not recruiting | USA | 0 |
| NCT04131621 | Phase II | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) | Unknown status | DEU | 0 |
| NCT04106414 | Phase II | Nivolumab Linrodostat + Nivolumab | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | Active, not recruiting | USA | 0 |
| NCT04464759 | Phase Ib/II | Nivolumab Hydroxychloroquine + Ipilimumab + Nivolumab Hydroxychloroquine + Nivolumab | A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (LIMIT) | Recruiting | USA | 0 |
| NCT05846659 | Phase II | Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Pembrolizumab | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | Active, not recruiting | USA | 0 |
| NCT03668119 | Phase II | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848) | Completed | USA | ROU | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | ARG | 3 |
| NCT02617589 | Phase III | Nivolumab Temozolomide | Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498) | Completed | USA | SWE | POL | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS | 2 |
| NCT02864316 | Phase II | Nivolumab | Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure | Terminated | USA | 0 |
| NCT01592370 | Phase Ib/II | Nivolumab Daratumumab + Nivolumab Daratumumab Ipilimumab + Nivolumab Daratumumab + Dexamethasone + Nivolumab + Pomalidomide Lirilumab + Nivolumab | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | Completed | USA | POL | ITA | GRC | FRA | BEL | 0 |
| NCT04099251 | Phase III | Nivolumab | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) | Active, not recruiting | USA | SWE | ROU | POL | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 0 |
| NCT02880020 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT04095208 | Phase II | Nivolumab + Relatlimab Nivolumab | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study (CONGRATS) | Recruiting | FRA | 0 |
| NCT04785820 | Phase II | RO7121661 Nivolumab RO7247669 | A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | Active, not recruiting | TUR | POL | ITA | HUN | GBR | FRA | ESP | DNK | CZE | BRA | ARG | 7 |
| NCT03580408 | Phase II | Nivolumab + Vinblastine Nivolumab | Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma | Completed | FRA | BEL | 0 |
| NCT03337919 | Phase II | Nivolumab | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (ANIMATE) | Active, not recruiting | GBR | 0 |
| NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
| NCT03329846 | Phase III | Linrodostat + Nivolumab Nivolumab | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | Completed | USA | POL | NZL | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 1 |
| NCT02194738 | Phase I | Nivolumab Crizotinib Erlotinib | Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | Recruiting | USA | 2 |
| NCT02466568 | Phase Ib/II | Nivolumab | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Withdrawn | 0 | |
| NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab Fexagratinib Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
| NCT02467361 | Phase Ib/II | Nivolumab Pembrolizumab Ipilimumab Napabucasin | A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers | Completed | USA | 0 |
| NCT03999749 | Phase II | Nivolumab Ipilimumab + Nivolumab + Tocilizumab | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | Active, not recruiting | USA | 0 |
| NCT03637543 | Phase II | Nivolumab | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT03519256 | Phase II | Linrodostat + Nivolumab Nivolumab BCG solution + Nivolumab BCG solution + Linrodostat + Nivolumab | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT) | Terminated | USA | NLD | ITA | GBR | FRA | ESP | CAN | BRA | AUS | ARG | 5 |
| NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Active, not recruiting | ITA | 0 |
| NCT03437200 | Phase II | Nivolumab Ipilimumab + Nivolumab | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL) | Terminated | FRA | ESP | 0 |
| NCT02985554 | Phase I | Nivolumab | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies | Terminated | USA | 0 |
| NCT03811015 | Phase II | Cisplatin Nivolumab Cisplatin + Nivolumab | Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer | Suspended | USA | 0 |
| NCT03815890 | Phase II | Nivolumab Ipilimumab + Nivolumab | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI) | Recruiting | NLD | 0 |
| NCT03134118 | Phase II | Nivolumab | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) (NIVOTHYM) | Active, not recruiting | NLD | GBR | FRA | ESP | CHE | BEL | 0 |
| NCT05310591 | Phase Ib/II | Cyclophosphamide + Fludarabine Nivolumab Tisagenlecleucel | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL) | Recruiting | FRA | 0 |
| NCT06019130 | Phase II | Cisplatin + Fluorouracil Cisplatin + Gemcitabine Nivolumab | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo) | Recruiting | DEU | 0 |
| NCT05681780 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | Recruiting | USA | 0 |
| NCT02743494 | Phase III | Nivolumab | Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUS | ARG | 10 |
| NCT04159818 | Phase II | Nivolumab Doxorubicin + Nivolumab Cisplatin + Nivolumab | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (TONIC-2) | Recruiting | NLD | 0 |
| NCT04062656 | Phase II | Nivolumab + Relatlimab Nivolumab Docetaxel + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (IMAGINE) | Active, not recruiting | DEU | 0 |
| NCT06054555 | Phase III | ABP 206 Nivolumab | A Study to Evaluate ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | Recruiting | USA | TUR | ROU | NLD | LTU | ITA | HRV | FRA | EST | ESP | DEU | CZE | CAN | ARG | 12 |
| NCT03245021 | Phase I | Nivolumab + Rituximab Nivolumab | Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A (1stFLOR) | Active, not recruiting | AUS | 0 |
| NCT01454102 | Phase I | Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | Completed | USA | CAN | 0 |
| NCT03325816 | Phase Ib/II | Nivolumab | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | Completed | USA | 0 |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT04021108 | Phase II | Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) | Active, not recruiting | USA | 0 |
| NCT03311958 | Phase I | Nivolumab | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | Active, not recruiting | USA | 0 |
| NCT03224871 | Phase I | Pembrolizumab Aldesleukin Nivolumab | A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | Completed | USA | 0 |
| NCT04848116 | Phase II | Cabiralizumab + Nivolumab BMS-986253 + Nivolumab Nivolumab | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (Spark2) | Recruiting | USA | 0 |
| NCT03436862 | Phase II | Nivolumab | Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression | Completed | USA | 0 |
| NCT02713867 | Phase III | Nivolumab | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS | 0 |
| NCT03016871 | Phase II | Nivolumab Carboplatin + Etoposide + Ifosfamide + Nivolumab | Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL | Active, not recruiting | USA | 0 |
CKB BOOST